Mouse monoclonal antibodies and immunohistochemical technique for determination of sex steroid receptors and human epidermal growth factor receptor in breast cancer

Ali Hassan AI-Timimi‎*1

Abstract

Breast cancer is one of the most common malignancies in women. The current study was conducted with the objective of assessing estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2/neu) reactivity patterns of breast cancers and to evaluate their association with clinicopathological features. Immunohistochemical (IHC) procedure was used to detect the expression of ER, PR and HER2/neu in postoperative paraffin blocks of breast tumors and statistically analyzed their correlations with clinicopathological characteristics. Most of the patients (66.0%) were ≤50 years at diagnosis. The left breast was more commonly involved (57%), tumor size ranged from 0.5 – 13.0 cm. The staining of Her2/neu was mainly localized in the membrane, whereas ER, PR, were localized in the nucleus. ER positivity was observed in 70% grade I, 48.2% grade II and 3.5% grade III carcinomas (P<0.05). Similarly PR positivity was observed in 70% grade I, 36.14% grade II and 1.75% grade III carcinomas (P<0.05). HER2/neu was positive in 1 (10%) case of grade I carcinoma, 31 (37.35%) cases of the grade II carcinoma and 24 (42.11%) cases of grade III carcinoma. In the HER-2/neu positive tumors, ER and PR expression in high grade tumors was significantly decreased compared with intermediate grade tumors (ER 5.6% vs 10.5; PR 0% vs 5.3%). Among the ER, PR and HER2/neu statuses, a significant correlation was observed between ER expression and PR status (P<0.05), whereas the expression of ER and PR exhibited a negative correlation with HER2 status (P<0.05). We also demonstrated a significant correlation between the HER2/neu subtypes with poor histological grade (P<0.05). In conclusion, there is a definite correlation between IHC indices and clinicopathological characteristics in breast carcinomas.

Keywords: Brest cancer; Progesterone; Estrogen; Her2/neu

Get Full Access/PDF

Be the first to comment

Leave a Reply

Your email address will not be published.


*